Get the latest news, insights, and market updates on NTRA (Natera, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
How Investors May Respond To NVIDIA (NVDA) Expanding Its AI Platform From Gaming To Drug Discovery
NVIDIA and its partners have, over recent days, unveiled a wave of new AI hardware and collaborations, from Blackwell-based GeForce RTX 5090 gaming cards and Vera Rubin data center systems to deep-life-sciences tie‑ups with Eli Lilly, Natera, Thermo Fisher and others built on the NVIDIA AI platform. Together, these launches and alliances extend NVIDIA’s AI reach from gaming and autonomous vehicles to drug discovery, industrial automation and privacy-first cloud infrastructure, reinforcing... Jan 20, 2026 - $NTRA
Exelixis, Inc. (EXEL) Sees Mixed Analyst Actions as Zanzalintinib Nears Commercial Launch
We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Exelixis, Inc. is placed eighth among the best cancer stocks. TheFly reported on January 8 that H.C. Wainwright analyst Robert Burns raised his price target on EXEL to $52 from $49 while maintaining a Buy rating after the company announced a […] Jan 20, 2026 - $NTRA
How Investors Are Reacting To Natera (NTRA) NVIDIA-Backed Multimodal AI And Precision Diagnostics Advances
Natera recently reported a series of advances, including an upgraded multi-modal Signatera MRD model, expanded AI collaborations with NVIDIA, new clinical data readouts in colorectal cancer, and further validation plus panel expansion for its Fetal Focus single-gene NIPT. Together, these developments highlight how Natera is increasingly leveraging one of the world’s largest longitudinal oncology datasets and AI tools to strengthen its position in precision diagnostics across oncology, organ... Jan 14, 2026 - $NTRA
Assessing Whether Natera (NTRA) Is Overvalued After Strong Longer Term Share Price Gains
Natera (NTRA) is on investors’ radar after recent trading left the shares at a last close of US$237.89, with returns varying widely across recent periods and performance metrics that raise fresh questions about valuation and growth. See our latest analysis for Natera. The recent 1 day share price return of 1.04% comes after a mixed few weeks, with a 7 day share price return of 4.36% compared to a stronger 90 day share price return of 32.59% and a 1 year total shareholder return of 43.51%... Jan 14, 2026 - $NTRA
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
AUSTIN, Texas, January 13, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced an advancement in molecular residual disease (MRD)-based risk stratification that is expected to extend the company’s leadership in oncology. The new multi-modal model will integrate longitudinal ctDNA and clinical data with digital pathology imaging and tumor sequencing data, to enhance the Signatera™ MRD assessment. Jan 13, 2026 - $NTRA
Genomic Testing Market Projected to Reach US$ 41.34 Billion by 2035, Supported by Rising Clinical Oncology Testing Volumes | Astute Analytica
The market is rapidly transitioning from episodic diagnostics to continuous health monitoring. By 2035, the integration of routine liquid biopsies and multiomics will standardize preventative care, democratizing access to precision medicine and fundamentally altering global healthcare delivery.Chicago, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The global genomic testing market was valued at USD 16.62 billion in 2025 and is projected to attain a valuation of USD 41.34 billion by 2035, at a CAGR of 9.54% Jan 13, 2026 - $NTRA
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA
AUSTIN, Texas, January 12, 2026--Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a new collaboration with NVIDIA to accelerate the development of Natera’s multimodal AI foundation model platform and expand applications across precision medicine. Jan 12, 2026 - $NTRA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple